Corneal Ulcer Pipeline Analysis & Clinical Trials Assessment, 2025, Delveinsight Ocunexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., Firststring Research, Regeneratetx, Stuart Therapeutic

(MENAFN- GetNews)


"Corneal ulcer Pipeline Analysis & Clinical Trials Assessment"DelveInsight's,“Corneal Ulcer – Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Corneal Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 15 leading companies are actively engaged in developing more than 15 therapies for the treatment of Corneal Ulcer.

Corneal ulcer Overview:

A corneal ulcer, also referred to as keratitis, is an open lesion on the cornea-the transparent outer layer covering the iris and pupil-much like a watch crystal shielding the face of a timepiece. While infections are the most common cause, severe dry eye and other ocular conditions can also trigger its onset.

This condition involves damage to both the corneal epithelium and the underlying stroma, making it a sight-threatening emergency. Even with prompt medical care, patients may experience serious complications, including corneal scarring, perforation, glaucoma, cataracts, synechiae (adhesions), and vision loss. In cases of untreated bacterial keratitis, the infection may progress to endophthalmitis and potentially result in complete loss of the eye.

Download our report @

"Corneal ulcer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Corneal ulcer Therapeutics Market.

Key Takeaways from the Corneal ulcer Pipeline Report

• DelveInsight's Corneal Ulcer pipeline report highlights a dynamic landscape with more than 15 active companies developing over 15 potential therapies for treatment.

• In March 2025, Glaukos Corporation submitted a New Drug Application (NDA) to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, which-if approved-would represent the first treatment of its kind.

• In January 2025, OKYO Pharma secured FDA Investigational New Drug (IND) clearance to begin clinical trials of OK-101 for corneal neuropathic pain (CNP), a condition that may lead to corneal ulcers. The program is currently in Phase 2 trials.

• Leading players in the Corneal Ulcer space include OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas Medicine, among others, all working on innovative drug candidates to expand treatment options.

• Promising pipeline therapies under investigation include Poliesanide, CODA001, synthetic FGF inhibitors, TTHX1114, and several additional candidates.

Corneal ulcer Pipeline Analysis

The Corneal ulcer pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Corneal ulcer Market.

• Categorizes Corneal ulcer therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Corneal ulcer drugs under development based on:

  • Stage of development

  • Corneal ulcer Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Corneal ulcer Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Corneal ulcer Licensing agreements

  • Funding and investment activities supporting future Corneal ulcer market advancement.

Request for a sample report @

Corneal ulcer Emerging Drugs

• Poliesanide: Sifi S.p.A

Sifi is advancing Poliesanide, which is currently in Phase III development for the treatment of Acanthamoeba Keratitis.

• CODA001: OcuNexus Therapeutics

CODA001 is an antisense oligonucleotide designed to inhibit the gap junction protein Cx43, which is upregulated in persistent epithelial defects. In a study by Ormonde et al., it was first administered to five eyes with severe ocular surface burns unresponsive to conventional therapies. Delivered using a Poloxamer407 gel in combination with either an amniotic membrane graft or a bandage contact lens, the treatment demonstrated rapid anti-inflammatory effects within 1–2 days and led to complete corneal reepithelialization. Originally developed by CODA Therapeutics, the drug is now being advanced into Phase II trials by OcuNexus Therapeutics.

• And more.

Corneal ulcer Companies

Approximately 15 major companies are working on developing therapies for Corneal Ulcer, with Sifi S.p.A and a few others having drug candidates in the most advanced stage of development, Phase III.

DelveInsight's report covers around 15+ products under different phases of Corneal ulcer clinical trials like

• Corneal ulcer Late stage Therapies (Phase III)

• Corneal ulcer Mid-stage Therapies (Phase II)

• Corneal ulcer Early-stage Therapies (Phase I)

• Corneal ulcer Pre-clinical and Corneal ulcer Discovery stage Therapies

• Corneal ulcer Discontinued & Inactive Therapies

Corneal ulcer pipeline report provides the Corneal ulcer therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Corneal ulcer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Corneal ulcer Therapies and Key Corneal ulcer Companies: Corneal ulcer Clinical Trials and recent advancements

Corneal ulcer Pipeline Therapeutic Assessment

. Corneal ulcer Assessment by Product Type

. Corneal ulcer By Stage

. Corneal ulcer Assessment by Route of Administration

. Corneal ulcer Assessment by Molecule Type

Download Corneal ulcer Sample report to know in detail about the Corneal ulcer treatment market @ Corneal ulcer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Corneal ulcer Current Treatment Patterns

4. Corneal ulcer - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Corneal ulcer Late-Stage Products (Phase-III)

7. Corneal ulcer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Corneal ulcer Discontinued Products

13. Corneal ulcer Product Profiles

14. Corneal ulcer Key Companies

15. Corneal ulcer Key Products

16. Dormant and Discontinued Products

17. Corneal ulcer Unmet Needs

18. Corneal ulcer Future Perspectives

19. Corneal ulcer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Corneal ulcer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN08092025003238003268ID1110033992